PD-1/PD-L1 plays critical roles in cancer immunology, and blocking antibodies against this receptor provide benefits in clinical trials, with the first of this class recently approved by the Food and Drug Administration (FDA) to treat patients with refractory malignancies [16]. The gene discussed is PDCD1; the disease is cancer.